e-learning
resources
2021
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK
Elisabeth Fenwick, Alan Martin, Melanie Schroeder, Stuart J. Mealing, Oyinkansola Solanke, Nancy Risebrough, Afisi S. Ismaila
Source:
ERJ Open Res, 7 (1) 00480-2020; 10.1183/23120541.00480-2020
Journal Issue:
January
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Elisabeth Fenwick, Alan Martin, Melanie Schroeder, Stuart J. Mealing, Oyinkansola Solanke, Nancy Risebrough, Afisi S. Ismaila. Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK. ERJ Open Res, 7 (1) 00480-2020; 10.1183/23120541.00480-2020
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Cost-effectiveness of a single inhaler triple therapy versus ICS/LABA in COPD
Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs
Year: 2018
Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial
Source: ERJ Open Res, 8 (1) 00333-2021; 10.1183/23120541.00333-2021
Year: 2022
The IMPACT of triple
versus
dual single-inhaler therapy on exacerbations of COPD
Source: Breathe, 14 (4) 333; 10.1183/20734735.026418
Year: 2018
Cost-effectiveness of fixed-dose combinations therapies for COPD in Spain
Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients?
Year: 2017
Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial
Source: Annual Congress 2009 - Functional insights into COPD
Year: 2009
Chinese subgroup results from a study comparing single-inhaler triple therapy with dual therapy in COPD
Source: International Congress 2017 – COPD management
Year: 2017
Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial
Source: Virtual Congress 2020 – Pharmacological management of COPD
Year: 2020
Effect of triple therapy with extra-fine BDP/FF/GB pMDI vs non-triple maintenance therapies on severe COPD exacerbations. A pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies.
Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more
Year: 2020
Characteristics and treatment pathways of patients with COPD receiving an inhaled corticosteroid/long-acting ß2-agonist (ICS/LABA) in the UK
Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data
Year: 2021
Cost-effectiveness of single- vs multiple-inhaler triple therapy in a UK COPD population: INTREPID trial
Source: Virtual Congress 2021 – Highlights for primary care in 2021
Year: 2021
Efficacy of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in COPD
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
LAMA/LABA vs. LABA/ICS and triple therapy – is ICS in again?
Source: International Congress 2018 – Preventing asthma and COPD exacerbations by increasing the inhaled glucocorticoid dose
Year: 2018
Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta
2
-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Triple therapy of umeclidinium and inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) vs placebo + ICS/LABA in GOLD D patients
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
A UK based cost-utility analysis of indacaterol – A once-daily maintenance bronchodilator for patients with COPD
Source: Annual Congress 2012 - Looking at the cost effectiveness of asthma and COPD treatment by novel drugs and improved management
Year: 2012
Free triple combination of glycopyrronium, indacaterol and ICS improves lung function and dyspnoea versus free double combination of indacaterol and ICS in patients with COPD: A post-hoc analysis from the GLOW6 study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Cost consequences of tiotropium plus existing therapy
versus
existing therapy alone following one year of treatment in patients with COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 5s
Year: 2001
Efficacy and safety of once-daily single-inhaler triple therapy in patients with inadequately controlled asthma: the CAPTAIN trial
Source: Breathe, 17 (1) 200279; 10.1183/20734735.0279-2020
Year: 2021
Estimated lifetime effectiveness of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) versus dual LAMA/LABA and ICS/LABA therapies in moderate-to-very severe COPD
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019
Overall and cardiovascular safety of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in patients with COPD
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept